Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells

BACKGROUND: Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms of acquired drug resistance to osimertinib have not as yet been clar...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Thorac Cancer
Main Authors: Hisakane, Kakeru, Seike, Masahiro, Sugano, Teppei, Yoshikawa, Akiko, Matsuda, Kuniko, Takano, Natsuki, Takahashi, Satoshi, Noro, Rintaro, Gemma, Akihiko
Formáid: Artigo
Teanga:Inglês
Foilsithe: John Wiley & Sons Australia, Ltd 2021
Ábhair:
Original Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8169289/
https://ncbi.nlm.nih.gov/pubmed/33939301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13943
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla